Secondly, tofacitinib as a targeted small molecule inhibitor of several JAK subtypes, acts on synovial JAK/STAT targets through IFN and IL-6 signaling pathways, thus blocking the role of JAK in synovial response to play a therapeutic role in RA [14,17,18]. Here, IFNA1 is linked to rheumatoid arthritis.